Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Using advanced computational genomics, Johns Hopkins investigators discovered how prostate cancer develops resistance to ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...